Verification of the Short-term Effect of SGLT2 Inhibitors on Serum Magnesium Stratified by the Classification of Albuminuria Severity in Patients with Type 2 Diabetes Mellitus
Abstract
Objective This study aimed to investigate the short-term effect of sodium/glucose cotransporter 2 inhibitors (SGLT2is) on serum magnesium (sMg) across three subgroups stratified according to the severity of albuminuria in patients with type 2 diabetes mellitus (T2DM). Methods Ninety patients were stratified into three subgroups according to their urinary albumin-to-creatinine ratio (UACR) at the initiation of SGLT2i treatment, according to the severity classification of albuminuria: A1 (normoalbuminuria; n=39), A2 (microalbuminuria; n=30), and A3 (macroalbuminuria; n=21). We evaluated the changes in sMg three months after the initiation of SGLT2i treatment in each subgroup. Subsequently, we compared the changes (Δ) in sMg levels across the three subgroups. Additionally, we investigated the baseline parameters correlated with Δ sMg, as well as the changes in parameters associated with Δ sMg. Results sMg was significantly increased in all subgroups (p<0.001 for A1, A2, and A3). Δ sMg was significantly different across the three subgroups (p=0.036), and Δ sMg in A3 was significantly greater than that in A1 (p=0.032). Δ sMg was positively correlated with baseline UACR (β=0.244, p=0.040) and inversely correlated with baseline sMg (β=-0.478, p<0.001). Δ sMg was positively correlated with Δ serum albumin level (β=0.239, p=0.033). Conclusion The short-term effect of SGLT2is on sMg levels was more pronounced in T2DM patients with macroalbuminuria.
Related
- Complementing Engel Classification: Postoperative Scalp EEG as an Objective Indicator in SEEG‐Guided Radiofrequency Thermocoagulation—A Seizure‐Onset Pattern‐Based Stratified Analysis—
- Availability of age-stratified evidence for GLP1 receptor agonists and SGLT2 inhibitors: an analysis of European public assessment reports with a focus on older patients
- Aldosterone synthase inhibitors in uncontrolled and resistant hypertension: A phenotype-stratified systematic review and network meta-analysis of randomized trials
- Conformance Verification of Healthcare Application Code Against Clinical Guidelines: A Case Study of Blood Pressure Classification
- Perineal Body Reconstruction for Anal Sphincter Insufficiency Following Obstetric Perineal Body Injury: Morphology-based Classification and Type-stratified Outcomes in 42 Cases.
BibTeX
@article{kitao2026verification,
title = {{Verification of the Short-term Effect of SGLT2 Inhibitors on Serum Magnesium Stratified by the Classification of Albuminuria Severity in Patients with Type 2 Diabetes Mellitus}},
author = {Takashi Kitao and Eriko Konishi and Motohiro Kubori and Yoshio Komoda and Yukiko Mori and Takeshi Ibata},
journal = {Internal Medicine},
year = {2026},
month = aug,
doi = {10.2169/internalmedicine.6548-25},
url = {https://www.jstage.jst.go.jp/article/internalmedicine/65/15/65_6548-25/_article},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Verification of the Short-term Effect of SGLT2 Inhibitors on Serum Magnesium Stratified by the Classification of Albuminuria Severity in Patients with Type 2 Diabetes Mellitus
AU - Takashi Kitao
AU - Eriko Konishi
AU - Motohiro Kubori
AU - Yoshio Komoda
AU - Yukiko Mori
AU - Takeshi Ibata
PY - 2026
DA - 2026/08/01
JO - Internal Medicine
DO - 10.2169/internalmedicine.6548-25
UR - https://www.jstage.jst.go.jp/article/internalmedicine/65/15/65_6548-25/_article
AB - Objective This study aimed to investigate the short-term effect of sodium/glucose cotransporter 2 inhibitors (SGLT2is) on serum magnesium (sMg) across three subgroups stratified according to the severity of albuminuria in patients with type 2 diabetes mellitus (T2DM). Methods Ninety patients were stratified into three subgroups according to their urinary albumin-to-creatinine ratio (UACR) at the initiation of SGLT2i treatment, according to the severity classification of albuminuria: A1 (normoalbuminuria; n=39), A2 (microalbuminuria; n=30), and A3 (macroalbuminuria; n=21). We evaluated the changes in sMg three months after the initiation of SGLT2i treatment in each subgroup. Subsequently, we compared the changes (Δ) in sMg levels across the three subgroups. Additionally, we investigated the baseline parameters correlated with Δ sMg, as well as the changes in parameters associated with Δ sMg. Results sMg was significantly increased in all subgroups (p<0.001 for A1, A2, and A3). Δ sMg was significantly different across the three subgroups (p=0.036), and Δ sMg in A3 was significantly greater than that in A1 (p=0.032). Δ sMg was positively correlated with baseline UACR (β=0.244, p=0.040) and inversely correlated with baseline sMg (β=-0.478, p<0.001). Δ sMg was positively correlated with Δ serum albumin level (β=0.239, p=0.033). Conclusion The short-term effect of SGLT2is on sMg levels was more pronounced in T2DM patients with macroalbuminuria.
SN - 1349-7235
SN - 0918-2918
ER -